---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-038225"
form_type: "8-K"
ticker: "BLFS"
cik: "0000834365"
company_name: "BIOLIFE SOLUTIONS INC"
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T08:14:38.111697+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# BioLife Solutions Q3 revenue falls 18% YoY; net loss widens to $29.1M on $15.5M impairment

## Summary
- Total revenue $33.3M, down 18% YoY; ex-COVID revenue down 10%.
- GAAP net loss $29.1M ($0.67 EPS) vs $10.3M loss in Q3 2022; includes $15.5M non-cash impairment.
- Biostorage and Services ex-COVID revenue grew 50% YoY; cell processing revenue down 26%.
- Cash $42.2M at quarter end; raised $10.4M via share sale in October 2023.
- FY2023 revenue guidance narrowed to low end of $144-158M; freezer divestiture expected in early 2024.

## SEC filing metadata
- accession: 0001628280-23-038225
- form_type: 8-K
- ticker: BLFS
- cik: 0000834365
- company_name: BIOLIFE SOLUTIONS INC
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/834365/000162828023038225/0001628280-23-038225-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/834365/000162828023038225/blfs-20231109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-038225
- JSON: https://secwatch.observer/filing/0001628280-23-038225.json
- Plain text: https://secwatch.observer/filing/0001628280-23-038225.txt

## Key facts
- Earnings Releases
  BIOLIFE SOLUTIONS INC reported third quarter ended September 30, 2023 results: revenue $33.3 million, net income Net loss (GAAP) for the third quarter of 2023 was $29.1 million, EPS Loss per share (GAAP) for the third quarter of 2023 was $0.67. Guidance reaffirmed.
  - Period: third quarter ended September 30, 2023
  - Revenue: $33.3 million
  - Net income: Net loss (GAAP) for the third quarter of 2023 was $29.1 million
  - EPS: Loss per share (GAAP) for the third quarter of 2023 was $0.67
  - Guidance: reaffirmed
  - Result: reported results
  source text: news release. 3303 Monte Villa Parkway, Suite 310 | Bothell, WA 98021 USA | 866.424.6543 phone | BioLifeSolutions.com REVENUE • Total revenue for the third quarter of 2023 was $33.3 million, a decrease of $7.4 million, or 18%, from $40.7 million for the third quarter of 2022. There was no COVID related revenue in the third quarter of 2023. Ex-COVID related revenue
  evidence_url: https://www.sec.gov/Archives/edgar/data/834365/000162828023038225/0001628280-23-038225-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.